They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease
Possible side effects may include mild redness at the injection site, temporary water retention, or slight changes in energy and appetite levels
The substantial quantity is perfectly suitable for extended research timelines and comprehensive dose-response investigations
rotate: Lamiophlomis rotate SM: Shanzhiside methylester MAPK: p38 mitogen-activated protein kinase DPN: Diabetic peripheral neuropathy MCU: Mitochondrial calcium uniporter UCP3: Uncoupling protein 3 DRP1: Dynamin-related protein 1 STZ: Streptozotocin ERK: Extracellular signal-regulated kinase MMP-2: Matrix metalloproteinases-2 MMP-9: Matrix metalloproteinases-9 NLRP3: NOD-like receptor protein 3 AGEs: Advanced glycation end products CSA: Cross-sectional area CM: Chronic migraine TNC: Trigeminal nucleus caudalis CGRP: Calcitonin gene-related peptide ICP: Intracranial pressure CSF: Cerebrospinal fluid IIH: Idiopathic intracranial hypertension References Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
They explained, While there have been no studies examining the effect of short-acting vs
Topical GHK-Cu is generally considered lower-risk than injectable forms, which may explain why it was in Category 1 rather than Category 2